Special Advertising

Pivotal Therapeutics Inc. (PVO:CNX) Stock Quote

Detailed Quote for Pivotal Therapeutics Inc. (PVO:CNX)
$ 0.075 0.00 (0.00%) Volume: 51k 3:34 PM EST Nov 21, 2014
Today 5d 1m 3m 1y more
Last Price
0.075
Change $
Change %
Tick
  
Bid
0.065
Bid Size
1,000
Ask
0.075
Ask Size
5,000
Open
0.065
High
0.075
Low
0.065
Prev Close
0.075
Last Trade
11/21/14
Volume
51k
52 Wk Hi
0.24
52 Wk Low
0.02
Market Cap
6.95m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
92,696,999
EPS (TTM)
-0.06
PE Ratio
N/A
Exchange
CSE
News and Media for Pivotal Therapeutics Inc. (PVO:CNX)
Sector News | Topic News
News for Pivotal Therapeutics Inc. (PVO:CNX)
Fri, Nov 14, 2014
3:15 PM Pivotal Therapeutics Announces Senior Management Change - Canada Newswire
3:15 PM Pivotal Therapeutics Announces Senior Management Change - PR Newswire
Wed, Oct 08, 2014
3:00 PM Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN\u00AE and Cholesterol Absorption Inhibitor - PR Newswire
12:44 PM Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN\u00AE and Cholesterol Absorption Inhibitor - Canada Newswire
12:44 PM Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN\u00AE and Cholesterol Absorption Inhibitor - PR Newswire
Tue, Oct 07, 2014
7:00 AM Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN\u00AE and Statin Therapy - PR Newswire
7:00 AM Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN\u00AE and Statin Therapy - Canada Newswire
7:00 AM Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN\u00AE and Statin Therapy - PR Newswire
Fri, Oct 03, 2014
2:37 PM Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes - Canada Newswire
2:37 PM Pivotal Therapeutics Announces Payment of Interest on Outstanding Convertible Notes - PR Newswire
Mon, Sep 15, 2014
5:42 PM Pivotal Therapeutics Grants Incentive Stock Options - Canada Newswire
5:42 PM Pivotal Therapeutics Grants Incentive Stock Options - PR Newswire
Wed, Sep 10, 2014
3:29 PM Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN\u00AE In The Correction of Omega-3 Deficiency In Cardiovascular Patients - PR Newswire
1:49 PM Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN\u00AE In The Correction of Omega-3 Deficiency In Cardiovascular Patients - Canada Newswire
1:49 PM Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN\u00AE In The Correction of Omega-3 Deficiency In Cardiovascular Patients - PR Newswire
Mon, Sep 08, 2014
11:50 AM Pivotal Appoints Accomplished Healthcare and Investment Industry Veteran, Prakash Gowd, as Chief Financial Officer - PR Newswire
11:50 AM Pivotal Appoints Accomplished Healthcare and Investment Industry Veteran, Prakash Gowd, as Chief Financial Officer - Canada Newswire
Wed, Sep 03, 2014
2:59 PM Unique Vasoprotective and Antihypertensive Effects of VASCAZEN\u00AE's Formulation Presented at ESC Congress 2014 - PR Newswire
2:19 PM Unique Vasoprotective and Antihypertensive Effects of VASCAZEN\u00AE's Formulation Presented at ESC Congress 2014 - Canada Newswire
2:19 PM Unique Vasoprotective and Antihypertensive Effects of VASCAZEN\u00AE's Formulation Presented at ESC Congress 2014 - PR Newswire
More News for PVO:CNX >>

Tags for Pivotal Therapeutics Inc.

Research stocks or mutual funds related to Pivotal Therapeutics Inc. by keywords or tags. Find companies that have a similar focus to PVO:CNX. The keywords below have been associated to PVO:CNX by either user submission or electronic means.